Martin C. Tammemägi
Professor
Health Sciences
Brock University
Canada
Biography
Dr. Tammemägi has a strong interest in cancer epidemiology with special interests in lung cancer screening and cancer risk prediction modeling. He has been a co-investigator and remains an active analyst in the U.S. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), the U.S, National Lung Screening Trial (NLST), and the Pan-Canadian Early Detection of Lung Cancer Study, and is an active associate member of the U.S. NIH NCI Cancer Intervention and Surveillance Modeling Network (CISNET) lung group. Dr. Tammemägi currently also serves as the Scientific Lead on Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk.
Research Interest
Cancer epidemiology; Cancer risk prediction modeling; Cancer screening, especially lung cancer screening
Publications
-
Patz EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, Chiles C, Black WC, Aberle DR, et al. Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer. JAMA Internal Medicine 2014 Feb 1;174(2):269-74.
-
Sin D, Tammemagi MC, Lam S, Barnett M, Duan X, Tam A, Auman H, Feng Z, Goodman G, Hanash S, Taguchi. Pro-Surfactant Protein B As A Biomarker For Lung Cancer Prediction. Journal of Clinical Oncology. 2013 Dec 20;31(36):4536-43. doi: 10.1200/JCO.2013.50.6105. Epub 2013 Nov 18.
-
Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J; National Lung Screening Trial Research Team. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013 Sep 5;369(10):920-31. doi: 10.1056/NEJMoa1208962.
-
Mehta HJ, Ravenel JG, Shaftman SR, Tanner NT, Paoletti L, Taylor KK, Tammemagi MC, Gomez M, Nietert PJ, Gould MK, Silvestri GA. The Utility of Nodule Volume in the Context of Malignancy Prediction for Small Pulmonary Nodules. CHEST. Chest. 2014 Mar 1;145(3):464-72. doi: 10.1378/chest.13-0708. PMID: 23949741.
-
Hocking WG, Tammemagi MC, Commins J, Oken MM, Kvale PA, Hu P, Ragard LR, Riley TL, Pinsky P, Beck TM, Prorok PC. Diagnostic evaluation following a positive lung screening chest radiograph in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial. Lung cancer (Amsterdam, Netherlands). 2013;82(2):238-44. PMID: 23993734.
-
Tammemagi M, Mayo J, Lam S. Cancer in Pulmonary Nodules Detected on First Screening CT – Reply to Correspondence to the Editor. The New England journal of medicine. 2013;369(21):2061-2.
-
McWilliams A, Tammemagi M, Mayo J, et al. Probability of cancer in pulmonary nodules detected on first screening computed tomography. New England Journal of Medicine. 2013;369;10:910-9.
-
de Koning H, Meza R, Plevritis S, ten Haaf K, Munshi V, Jeon J, Erdogan S, Kong C, Han S, Rosmalen J, Choi S, Miller M, Moolgavkar SH, Pinsky P, Berg CD, Berrington De Gonzalez A, Black W, Tammemagi MC, Hazelton W, Feuer E, McMahon P. Benefits and Harms of Computed Tomography Lung Cancer Screening Programs for High-Risk Populations. AHRQ Publication No. 13-05196-EF-2. Rockville, MD: Agency for Healthcare Research and Quality, 2013.
-
Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, Misumi S, Kwon KS. Interstitial Lung Abnormalities in a CT Lung Cancer Screening Population: Prevalence and Progression Rate. Radiology. 2013;268(2):563-71
-
Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, Silvestri GA, Chaturvedi AK, Katki HA. Targeting of low-dose CT screening according to the risk of lung-cancer death. New England Journal of Medicine. 2013;369(3):245-54.
